The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China

To evaluate the outcomes of neoadjuvant chemotherapy (NACT) for patients with advanced epithelial ovarian cancer (EOC), and to identify predictors of response to NACT by analyzing the characteristics of patients and guiding future therapy choices in China. Three to four courses of NACT followed by interval cytoreductive surgery (ICS) were utilized to treat advanced EOC patients. The median overall survival (OS) in NACT response group was significantly longer than that of the no response group. Patients with International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV were more likely to respond to NACT. Optimal cytoreductive surgery (OCS was achieved in 80 (70.2%) patients among 114, and complete cytoreductive surgery (CCS) was achieved in 34 (29.8%) patients. The median OS of patients with no residual tumor was significantly longer than those with residual tumors of 0.1−1.0 cm. The median OS of the ten patients who did not receive surgery was notably worse than patients with residual tumor > 1.0 cm. CA125 sensitivity and specificity were 40.8% and 86.7%, respectively. Present studies provided evidences that NACT was a viable remedy for patients with advanced EOC in China.

Epithelial ovarian cancer (EOC); Neoadjuvant chemotherapy (NACT); Interval cytoreductive surgery (ICS).

[1] Siegel R., Ma J., Zou Z., Jemal A.: “Cancer statistics, 2014”. CA Cancer J. Clin., 2014, 64, 9.

[2] Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J.: “Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis”. J. Clin. Oncol., 2002, 20, 1248.

[3] Kang S., Nam B.H.: “Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies”. Ann. Surg. Oncol., 2009, 16, 2315.

[4] Hegazy M.A., Hegazi R.A., Elshafei M.A., Setit A.E., Elshamy M.R., Eltatoongy M., et al.: “Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma”. World J. Surg. Oncol., 2005, 3, 57.

[5] Hou J.Y., Kelly M.G., Yu H., McAlpine J.N., Azodi M., Rutherford T.J., et al.: “Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease”. Gynecol. Oncol., 2007, 105, 211.

[6] Milam M.R., Tao X., Coleman R.L., Harrell R., Bassett R., Dos Reis R., et al.: “Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer”. Int. J. Gynecol. Cancer, 2011, 21, 66.

[7] Vergote I., van Gorp T., Amant F., Neven P., Berteloot P.: “Neoadjuvant chemotherapy for ovarian cancer”. Oncology, 2005, 19, 1615.

[8] Mazzeo F., Berlière M., Kerger J., Squifflet J., Duck L., D’Hondt V., et al.: “Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer”. Gynecol. Oncol., 2003, 90, 163.

[9] Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al.: “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)”. Eur. J. Cancer, 2009, 45, 228.

[10] Rustin G.J., Vergote I., Eisenhauer E., Pujade-Lauraine E., Quinn M., Thigpen T., et al.: “Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)”. Int. J. Gynecol. Cancer, 2011, 21, 419.

[11] Bristow R.E., Chi D.S.: “Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis”. Gynecol. Oncol., 2006, 103, 1070.

[12] Polcher M., Mahner S., Ortmann O., Hilfrich J., Diedrich K., Breitbach G.P., et al.: “Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer—a prospective multicenter phase II trial (PRIMOVAR)”. Oncol. Rep., 2009, 22, 605.

[13] Onda T., Yoshikawa H., Yasugi T., Matsumoto K., Taketani Y.: “The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment”. Jpn. J. Clin. Oncol., 2010, 40, 36.

[14] Le T., Alshaikh G., Hopkins L., Faught W., Fung M.F.: “Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking”. Ann. Surg. Oncol., 2006, 13, 1711.

[15] Norton L., Simon R.: “Tumor size, sensitivity to therapy, and design of treatment schedules”. Cancer Treat. Rep., 1997, 61, 307.

[16] Yildirim Y., Ertas I.E., Dogan A., Gultekin O.E., Gultekin E.: “The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer”. J. Surg. Oncol., 2012, 105, 200.

[17] Covens A.L.: “A critique of surgical cytoreduction in advanced ovarian cancer”. Gynecol. Oncol., 2000, 78, 269.